Compare CISO & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CISO | KALA |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 13.3M |
| IPO Year | 2021 | 2017 |
| Metric | CISO | KALA |
|---|---|---|
| Price | $0.23 | $0.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 228.4K | ★ 353.5K |
| Earning Date | 05-15-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.31 | 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.07 |
| 52 Week High | $1.48 | $20.58 |
| Indicator | CISO | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 46.48 | 30.22 |
| Support Level | $0.21 | $0.10 |
| Resistance Level | $0.32 | $0.72 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 54.47 | 2.92 |
CISO Global Inc provides cybersecurity compliance and is a software firm composed of trained and seasoned security professionals. The services are used to protect clients' data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in the U.S., Chile, and all other countries. The maximum revenue is generated from the U.S. The products and services include: security managed services, professional services, and cybersecurity software.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.